This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $563,588 to Weill Medical College of Cornell University to study the effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity, and clinical outcomes of COVID-19. The research aims to determine the immune defects linked to prolonged SARS-CoV-2 replication in immunocompromised hosts, and ascertain the effect of different immunosuppressive conditions and therapies on viral genetic diversity. The findings are expected to advance the understanding of immune mechanisms involved in SARS-CoV-2 persistence in immunocompromised individuals and inform the development of optimal therapies and public health interventions to prevent the emergence and spread of new viral variants. The award period is from July 2024 to May 2026.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $29.7k | 9/11/24 | ||
| Not listed | $267.0k | 7/9/24 | ||
| Not listed | $267.0k | 7/9/24 |